Scandinavian ChemoTech AB Series B (CMOTEC-B) - Net Assets
Based on the latest financial reports, Scandinavian ChemoTech AB Series B (CMOTEC-B) has net assets worth Skr6.19 Million SEK (≈ $666.47K USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr17.38 Million ≈ $1.87 Million USD) and total liabilities (Skr11.18 Million ≈ $1.20 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read CMOTEC-B liabilities breakdown for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr6.19 Million |
| % of Total Assets | 35.64% |
| Annual Growth Rate | 62.6% |
| 5-Year Change | -35.25% |
| 10-Year Change | 588.44% |
| Growth Volatility | 672.76 |
Scandinavian ChemoTech AB Series B - Net Assets Trend (2014–2024)
This chart illustrates how Scandinavian ChemoTech AB Series B's net assets have evolved over time, based on quarterly financial data. Also explore CMOTEC-B current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Scandinavian ChemoTech AB Series B (2014–2024)
The table below shows the annual net assets of Scandinavian ChemoTech AB Series B from 2014 to 2024. For live valuation and market cap data, see Scandinavian ChemoTech AB Series B (CMOTEC-B) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr5.98 Million ≈ $643.54K |
-45.79% |
| 2023-12-31 | Skr11.03 Million ≈ $1.19 Million |
-21.16% |
| 2022-12-31 | Skr13.99 Million ≈ $1.51 Million |
-41.50% |
| 2021-12-31 | Skr23.92 Million ≈ $2.57 Million |
+158.95% |
| 2020-12-31 | Skr9.24 Million ≈ $993.94K |
-5.07% |
| 2019-12-31 | Skr9.73 Million ≈ $1.05 Million |
-52.53% |
| 2018-12-31 | Skr20.50 Million ≈ $2.21 Million |
+99.23% |
| 2017-12-31 | Skr10.29 Million ≈ $1.11 Million |
-29.46% |
| 2016-12-31 | Skr14.58 Million ≈ $1.57 Million |
+1578.88% |
| 2015-12-31 | Skr868.64K ≈ $93.48K |
+1777.36% |
| 2014-12-31 | Skr46.27K ≈ $4.98K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Scandinavian ChemoTech AB Series B's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1371140600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr11.67 Million | 195.18% |
| Other Comprehensive Income | Skr-108.87 Million | -1820.55% |
| Other Components | Skr116.89 Million | 1954.75% |
| Total Equity | Skr5.98 Million | 100.00% |
Scandinavian ChemoTech AB Series B Competitors by Market Cap
The table below lists competitors of Scandinavian ChemoTech AB Series B ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Radiant Utama Interinsco Tbk
JK:RUIS
|
$10.11 Million |
|
Ostin Technology Group Co Ltd
NASDAQ:OST
|
$10.11 Million |
|
Intelicanna Ltd
TA:INTL
|
$10.11 Million |
|
Intrasense
PA:ALINS
|
$10.11 Million |
|
Globe Kita Terang Tbk PT
JK:GLOB
|
$10.09 Million |
|
Memphasys Ltd
AU:MEM
|
$10.07 Million |
|
AUX Resources Corporation
V:AUX
|
$10.07 Million |
|
Burford Capital Limited
LSE:BUR
|
$10.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Scandinavian ChemoTech AB Series B's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 11,031,000 to 5,980,000, a change of -5,051,000 (-45.8%).
- Net loss of 13,717,000 reduced equity.
- Share repurchases of 8,546,000 reduced equity.
- New share issuances of 8,546,000 increased equity.
- Other comprehensive income decreased equity by 20,971,000.
- Other factors increased equity by 29,637,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-13.72 Million | -229.38% |
| Share Repurchases | Skr8.55 Million | -142.91% |
| Share Issuances | Skr8.55 Million | +142.91% |
| Other Comprehensive Income | Skr-20.97 Million | -350.69% |
| Other Changes | Skr29.64 Million | +495.6% |
| Total Change | Skr- | -45.79% |
Book Value vs Market Value Analysis
This analysis compares Scandinavian ChemoTech AB Series B's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 15.38x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 150.96x to 15.38x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | Skr0.03 | Skr3.94 | x |
| 2014-12-31 | Skr0.03 | Skr3.94 | x |
| 2015-12-31 | Skr0.76 | Skr3.94 | x |
| 2016-12-31 | Skr9.98 | Skr3.94 | x |
| 2017-12-31 | Skr7.03 | Skr3.94 | x |
| 2018-12-31 | Skr6.28 | Skr3.94 | x |
| 2019-12-31 | Skr2.37 | Skr3.94 | x |
| 2020-12-31 | Skr1.88 | Skr3.94 | x |
| 2021-12-31 | Skr2.76 | Skr3.94 | x |
| 2022-12-31 | Skr1.40 | Skr3.94 | x |
| 2023-12-31 | Skr0.79 | Skr3.94 | x |
| 2024-12-31 | Skr0.26 | Skr3.94 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Scandinavian ChemoTech AB Series B utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -229.38%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -208.91%
- • Asset Turnover: 0.49x
- • Equity Multiplier: 2.24x
- Recent ROE (-229.38%) is below the historical average (-107.23%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -16.80% | 0.00% | 0.00x | 1.00x | Skr-11.90K |
| 2014 | -60.81% | 0.00% | 0.00x | 1.42x | Skr-32.76K |
| 2015 | -135.94% | -8498.88% | 0.00x | 7.66x | Skr-1.27 Million |
| 2016 | -55.81% | -390.48% | 0.12x | 1.15x | Skr-9.60 Million |
| 2017 | -80.99% | -30582.56% | 0.00x | 1.25x | Skr-9.36 Million |
| 2018 | -23.41% | -856.61% | 0.02x | 1.11x | Skr-6.85 Million |
| 2019 | -129.36% | -2263.49% | 0.03x | 1.80x | Skr-13.56 Million |
| 2020 | -126.29% | -8903.82% | 0.01x | 1.73x | Skr-12.59 Million |
| 2021 | -74.19% | -36210.20% | 0.00x | 1.08x | Skr-20.13 Million |
| 2022 | -162.56% | -4808.88% | 0.02x | 1.55x | Skr-24.15 Million |
| 2023 | -191.20% | -747.38% | 0.19x | 1.35x | Skr-22.19 Million |
| 2024 | -229.38% | -208.91% | 0.49x | 2.24x | Skr-14.31 Million |
Industry Comparison
This section compares Scandinavian ChemoTech AB Series B's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $218,788,642
- Average return on equity (ROE) among peers: -65.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Scandinavian ChemoTech AB Series B (CMOTEC-B) | Skr6.19 Million | -16.80% | 1.81x | $10.09 Million |
| 2cureX AB (2CUREX) | $7.91 Million | -8.20% | 0.37x | $5.08 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $41.16 Million |
| AcouSort AB (ACOU) | $9.96 Million | -8.34% | 0.21x | $8.79 Million |
| Active Biotech AB (ACTI) | $53.78 Million | -67.06% | 0.24x | $17.13 Million |
| Alzinova AB (ALZ) | $947.42K | -195.83% | 0.18x | $4.92 Million |
| AlzeCure Pharma (ALZCUR) | $233.17 Million | -15.43% | 0.02x | $17.50 Million |
| Annexin Pharmaceuticals AB (ANNX) | $30.15 Million | -135.06% | 0.22x | $11.51 Million |
| Alligator Bioscience AB (ATORX) | $676.18 Million | -7.15% | 0.04x | $14.40 Million |
| BioInvent International AB (BINV) | $87.62 Million | -140.56% | 0.37x | $157.92 Million |
| BioArctic AB (publ) (BIOA-B) | $907.30 Million | -7.55% | 0.16x | $2.62 Billion |
About Scandinavian ChemoTech AB Series B
Scandinavian ChemoTech AB (publ), a medical technology company, engages in the radiation physics, surgical oncology, and clinical development in Sweden and internationally. It operates in two divisions, Human Care and Animal Care. The company offers IQWave, an electroporation that generates a tumour-specific electrical stimulation; and veterinary medicines under the vetIQur name. Scandinavian Che… Read more